-
公开(公告)号：US20200262852A1
公开(公告)日：2020-08-20
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang
IPC: C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US09567339B2
公开(公告)日：2017-02-14
申请号：US14315504
申请日：2014-06-26
Applicant: AbbVie Inc.
Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D487/04 , C07D417/12 , C07D471/04 , C07D209/08 , C07D417/14 , C07D401/14 , C07D403/14 , C07D231/56 , C07D401/12
CPC classification number: C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号：US20160031838A1
公开(公告)日：2016-02-04
申请号：US14812726
申请日：2015-07-29
Applicant: AbbVie Inc.
Inventor： Gary G. Chiang , William N. Pappano , Ramzi F. Sweis , Zhi Wang
IPC: C07D265/36 , C07C255/58 , C07D471/04 , C07D401/12 , C07D209/40 , C07D295/13 , C07D487/04
CPC classification number: C07D265/36 , C07C255/58 , C07C2601/14 , C07D209/40 , C07D295/13 , C07D401/12 , C07D471/04 , C07D487/04
Abstract: The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
Abstract translation: 本公开内容通常涉及具有细胞抗增殖活性的化合物，更具体地涉及抑制人SMYD2，SET和MYND结构域的蛋白赖氨酸甲基转移酶的活性的化合物。
-
公开(公告)号：US20240024338A1
公开(公告)日：2024-01-25
申请号：US18334738
申请日：2023-06-14
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao. , Xiaochun Lou , Sean Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
CPC classification number: A61K31/661 , A61K9/0019 , A61K9/14 , A61K45/06 , A61K9/08 , C07F9/12
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20170174624A1
公开(公告)日：2017-06-22
申请号：US15398978
申请日：2017-01-05
Applicant: AbbVie Inc.
Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D209/08 , C07D405/14 , C07D403/04 , C07D401/04 , C07D209/18 , C07D405/04 , C07D209/12 , C07D209/10 , C07D209/14 , C07D417/14 , C07D401/14 , C07D409/14 , C07D403/10 , C07D409/04 , C07D409/12 , C07D403/14 , C07D413/04
CPC classification number: C07D209/08 , A61P35/00 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
Patent Agency Ranking
公开(公告)号：US09598381B2
公开(公告)日：2017-03-21
申请号：US14812726
申请日：2015-07-29
Applicant: AbbVie Inc.
Inventor： Gary G. Chiang , William N. Pappano , Ramzi F. Sweis , Zhi Wang
IPC: C07D209/40 , C07D265/36 , C07D295/13 , C07D487/04 , C07D401/12 , C07D471/04 , C07C255/58
CPC classification number: C07D265/36 , C07C255/58 , C07C2601/14 , C07D209/40 , C07D295/13 , C07D401/12 , C07D471/04 , C07D487/04
Abstract: The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
-
公开(公告)号：US20150005279A1
公开(公告)日：2015-01-01
申请号：US14315504
申请日：2014-06-26
Applicant: ABBVIE INC.
Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D487/04 , C07D471/04 , C07D209/08 , C07D401/12 , C07D401/14 , C07D403/14 , C07D231/56 , C07D417/12 , C07D417/14
CPC classification number: C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号：US20220153765A1
公开(公告)日：2022-05-19
申请号：US17378321
申请日：2021-07-16
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20210179556A1
公开(公告)日：2021-06-17
申请号：US17173613
申请日：2021-02-11
Applicant: AbbVie Inc.
Inventor： Dominique Bonafoux , Heather Michele Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep Kaur Somal , Jennifer Van Camp , Stacy Anne Van Epps , Anil Vasudevan , Grier Allan Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D209/08 , C07D487/04 , C07D417/12 , C07D471/04 , C07D417/14 , C07D401/14 , C07D403/14 , C07D231/56 , C07D401/12 , A61P35/00 , C07D513/04 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
公开(公告)号：US20190375770A1
公开(公告)日：2019-12-12
申请号：US16210996
申请日：2018-12-05
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christiopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.033 seconds)
